- Trial Phase
- Phase 1b (completed, open-label extension ongoing); FDA IND cleared for Phase 2a (starting Q3 2026)
- Time to Market
- Estimated 4-6+ years if Phase 2a (48-week, double-blind) succeeds and is followed by a pivotal Phase 3 program
- Why 7/10
- The next hard catalyst is the Phase 1b 9-month extension topline data (~September 2026), ~3 months out. GT-02287 is the company's only significant asset, driving essentially all of GANX's ~$85M market cap. However, the extension data is open-label and not a pivotal readout, capping the score below 9–10.
Watch for Phase 1b 9-month extension data (~September 2026) — positive results could drive a sharp re-rating given the >300% analyst implied upside, but the company has only ~3-4 quarters of cash runway at a ~$4.7M/quarter burn rate, making near-term dilution or a dilutive financing highly likely. Any financing announcement would likely cap upside.
Price Chart
Executive Summary
GT-02287 is Gain Therapeutics' only clinical-stage asset — a first-in-class oral GCase chaperone for Parkinson's disease, particularly in patients with GBA1 gene mutations (the largest known genetic risk factor for Parkinson's). Phase 1b data showed encouraging biomarker and clinical signals (81% reduction in CSF GluSph, stable MDS-UPDRS scores) in a small open-label study. The FDA just cleared the IND for a Phase 2a trial (June 29, 2026). However, the company faces severe financial constraints: $16.5M cash with a ~$4.7M/quarter burn rate and a going-concern warning. Analyst consensus is strongly bullish (10 of 11 analysts rate Buy/Strong Buy, mean target $7.20 vs ~$1.91), but Parkinson's is a notoriously tough indication where many promising drugs have failed, and the promising Phase 1b data came from just 21 patients in an open-label design.
How It Works
GT-02287 is an oral pill that helps fix a broken enzyme called glucocerebrosidase (GCase) in brain cells. In people with Parkinson's — especially those with a GBA1 gene mutation (up to 15% of patients) — this enzyme misfolds and stops working, leading to toxic protein buildup and cell death. GT-02287 acts like a molecular 'chaperone,' binding to the enzyme to help it fold correctly and restore its function, potentially slowing or modifying the course of the disease.
Trial Status
Phase 1b enrolled 21 patients with Parkinson's across 7 Australian sites, completed the 3-month primary endpoint (safety/tolerability) with positive biomarker and clinical signals. 16 of 16 eligible patients continued into a 9-month open-label extension expected to conclude ~September 2026. FDA cleared the IND for a 48-week placebo-controlled Phase 2a trial on June 29, 2026, with enrollment expected to begin in Q3 2026 across U.S., Australian, and European sites.
The Two-Sided Case
Upcoming Catalysts
- Phase 1b 9-month open-label extension topline data (~September 2026)
- Phase 2a trial initiation in the U.S., Australia, and Europe (Q3 2026)
- Any partnership, licensing, or financing announcements to extend cash runway
- Additional preclinical or translational data presentations at neurology conferences (e.g., 7th World Parkinson's Congress, May 2026 already occurred)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Gain Therapeutics, Inc. 8-K GANX ·Originating report